Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Tenecteplase a Basso Dosaggio per il Trattamento dell'Ictus Ischemico Acuto nei Pazienti Anziani (DATE-AGING)

1 novembre 2026 aggiornato da: Zhenhua Zhou, Southwest Hospital, China

Efficacia e Sicurezza della Tenecteplasi a Basso Dosaggio nel Trattamento dell'Ictus Ischemico Acuto in Pazienti Anziani: Uno Studio Prospettico, Multicentrico, Randomizzato e Controllato

The DATE-AGING study is a prospective, multicenter, randomized controlled trial investigating low-dose tenecteplase in elderly patients with acute ischemic stroke. Its primary objective is to evaluate the safety and efficacy of low-dose tenecteplase in elderly patients within 4.5 hours of acute ischemic stroke onset.

Panoramica dello studio

Tipo di studio

Interventistico

Iscrizione (Effettivo)

806

Fase

  • Fase 4

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

      • Anshan, Cina
        • Anshan Changda Hospital
      • Anyang, Cina
        • Anyang People's Hospital
      • Anyang, Cina
        • Huaxian People's Hospital of Henan
      • Baoshan, Cina
        • Baoshan People's Hospital
      • Bijie, Cina
        • People's Hospital of Zhijin County
      • Chongqing, Cina
        • Chongqing University Three Gorges Hospital
      • Chongqing, Cina
        • Chongqing University Jiangjin Hospital
      • Chongqing, Cina
        • Bishan Hospital
      • Chongqing, Cina
        • Chongqing Emergency Medical Center
      • Chongqing, Cina
        • Chongqing University Fuling Hospital
      • Chongqing, Cina
        • Dianjiang People's Hospital OF Chongqing
      • Chongqing, Cina
        • People's Hospital Of Xiushan County
      • Chongqing, Cina
        • The People's Hospital of Dazu Chongqing
      • Chongqing, Cina
        • The People's Hospital of HeChuan, Chongqing
      • Chongqing, Cina
        • The People's Hospital of Rongchang Chongqing
      • Chongqing, Cina
        • The People's Hospital of Tongnan District Chongqing City
      • Chongqing, Cina
        • The Seventh People's Hospital of Chongqing
      • Chongqing, Cina
        • Tongliang Hospital
      • Chongqing, Cina
        • Yunyang County People's Hospital
      • Dali, Cina
        • Dali Bai Autonomous Prefecture People's Hospital
      • Dazhou, Cina
        • Dazhou Central Hospital
      • Deyang, Cina
        • The People's Hospital of Zhongjiang
      • Guang’an, Cina
        • Guang an People's Hospital
      • Guiyang, Cina
        • Guizhou Provincial People's Hospital
      • Guiyang, Cina
        • The Second People's Hospital of Guiyang(Guiyang Jinyang Hospital)
      • Ha’erbin, Cina
        • The First Affiliated Hospital of Harbin Medical University
      • Hebi, Cina
        • Xunxian People's Hospital
      • Heyuan, Cina
        • Heyuan People's Hospital
      • Huanggang, Cina
        • Qichun People's Hosiptal
      • Jianyang, Cina
        • The People's Hospital Of Jianyang City
      • Laixi, Cina
        • Laixi People's Hospital
      • Leshan, Cina
        • People's Hospital of Leshan
      • Leshan, Cina
        • Leshan Geriatric Specialized Hospital
      • Luoyang, Cina
        • Luoyang Mengjin People's Hospital
      • Nanchong, Cina
        • Nanbu People's Hospital
      • Pujiang, Cina
        • Puyang People's Hospital
      • Pujiang, Cina
        • The People's Hospital of Nan Le Xian
      • Shangqiu, Cina
        • People's Hospital of Ningling County
      • Shangqiu, Cina
        • The First People's Hospital of Shangqiu
      • Shaoyang, Cina
        • The First People ' S Hospital of Shao Yang
      • Shijiazhuang, Cina
        • The People's Hospital of Gaocheng
      • Wuhan, Cina
        • Wuhan Puren Hospital
      • Xiangyang, Cina
        • Xiangyang NO.1 People's Hospital
      • Yibin, Cina
        • The second people's hospital of Yibin
      • Zhumadian, Cina
        • Zhumadian Central Hospital
      • Zhuzhou, Cina
        • Zhuzhou Central Hospital
      • Zigong, Cina
        • Zigong Third People's Hospital
      • Ziyang, Cina
        • Ziyang Central Hospital
    • Chongqing Municipality
      • Chongqing, Chongqing Municipality, Cina, 400038
        • Southwest Hospital, Chongqing, China
    • Heilongjiang
      • Harbin, Heilongjiang, Cina, 150200
        • Wuchang People's Hospital
    • Henan
      • Zhoukou, Henan, Cina, 466300
        • Shenqiu County People's Hospital

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

70 anni e precedenti (Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  1. Age ≥ 70 years;
  2. Diagnosis of ischaemic stroke with a measurable neurological deficit on National Institutes of Health Stroke Scale (NIHSS) (1≤ NIHSS ≤25); if NIHSS <4, patients have to be with at least a measurable deficit on motor power (upper or lower limbs ≥1);
  3. Stroke symptoms should have been present for at least 30 minutes (min) without significant improvement prior to randomisation;
  4. Thrombolytic therapy can be initiated within 4.5 Hour(s) (h) of Acute ischaemic stroke (AIS) onset;
  5. Patients with premorbid modified Rankin Scale (mRS) 0 or 1;
  6. Informed consent from the patient or surrogate.

Exclusion Criteria:

  1. Imaging demonstrates multi-lobar infarction (hypodensity >1/3 cerebral hemisphere);

  2. Acute bleeding diathesis or allergy to tenecteplase, including but not limited to

    • Known genetic predisposition to bleeding or significant bleeding disorder at present or within the past 6 Month(s) (m)
    • Administration of heparin within the previous 48 h and activated partial thromboplastin time (aPTT) exceeding the upper limit of normal for laboratory measurement
    • Current use of vitamin K based oral anticoagulants (e.g. warfarin) and a prolonged prothrombin time (International normalised Ratio (INR) > 1.7 or Prothrombin time (PT)>15 seconds (s)) or current use of novel oral anticoagulants (i.e. dabigitran, rivaroxiban, or apixiban) with prolongation of activated partial thromboplastin time (aPTT) and/or PT above the upper limit of the local laboratory reference range
    • Platelet count of below 100×10^9/ L
    • Any history of central nervous system damage (i.e. neoplasm, aneurysm, intracranial or spinal surgery)
    • Recent traumatic external heart massage or recent puncture of a non-compressive blood-vessel (e.g. subclavian or jugular vein puncture) , within the past 10 days
    • Known history of suspected intracranial haemorrhage or suspected subarachnoid haemorrhage from aneurysm
    • Neoplasm with increased haemorrhagic risk
    • Documented ulcerative gastrointestinal disease during the last 3 months, oesophageal varices, arterial aneurysm, or arterial/venous malformations
    • History of significant trauma or major surgery within the past 3 months.
    • Any known disorder associated with a significant increased risk of bleeding
  3. Intracranial hemorrhage (including parenchymal hemorrhage, intraventricular hemorrhage, subarachnoid hemorrhage, subdural/extradural hematoma, etc.);

  4. Blood glucose <2.8 mmol/L or >22.22 mmol/L;

  5. After active antihypertensive treatment, hypertension is still not under control: systolic blood pressure ≥180 mmHg, or diastolic blood pressure ≥100 mmHg;

  6. Seizure at stroke onset;

  7. Concurrent malignancy or severe systemic disease with an anticipated survival of less than 90 days;

  8. Participation in other clinical trials within 3 months prior to screening;

  9. Unsuitability or participation in this study as judged by the Investigator may result in subjects being exposed to greater risk.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Separare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Low-Dose Tenecteplase

0.175mg/kg tenecteplase

Subjects will be randomized to low-dose group or standard-dose group in a 1:1 ratio. Patients in the low-dose group received tenecteplase (0.175 mg/kg) for intravenous thrombolysis. The upper dose limit is set to 17.5 mg/patient.

Comparatore attivo: Standard-Dose Tenecteplase

0.25mg/kg tenecteplase

Subjects will be randomized to low-dose group or standard-dose group in a 1:1 ratio. Patients in the standard-dose group received tenecteplase (0.25 mg/kg) for intravenous thrombolysis. The upper dose limit is set to 25 mg/patient.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Percentage of Participants With Modified Rankin Scale (mRS) Score of 0 or 1
Lasso di tempo: At Day 90±7 days

Modified Rankin Scale (mRS) is a standardized measure that describes the extent of disability after a stroke. The mRS is a single item scale. It increases from 0 (no symptoms at all) to 6 (death).

At Day 90±7 days

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Percentage of participants with major neurological improvement (National Institutes of Health Stroke Scale (NIHSS) score of 0 or improvement of at least 4 points compared with baseline)
Lasso di tempo: At 24 hours

National Institutes of Health Stroke Scale (NIHSS) is a 11-item neurologic examination stroke scale used to evaluate the effect of acute cerebral infarction on the levels of consciousness, language, neglect, visual-field loss, extraocular movement, motor strength, ataxia, dysarthria, and sensory loss. A trained observer rates the patent's ability to answer questions and perform activities. Ratings for each item are scored with 3 to 6 grades with 0 as normal, and there is an allowance for untestable items.Total NIHSS score (0-42) = sum of 11 individual item scores, higher total scores meaning more severe deficits.

At 24 hours
Percentage of Participants With Modified Rankin Scale (mRS) Score of 0-2
Lasso di tempo: At Day 90±7 days

Modified Rankin Scale (mRS) is a standardized measure that describes the extent of disability after a stroke. The mRS is a single item scale. It increases from 0 (no symptoms at all) to 6 (death).

At Day 90±7 days
Distribution of Modified Rankin Scale (mRS)
Lasso di tempo: At Day 90±7 days

Modified Rankin Scale (mRS) is a standardized measure that describes the extent of disability after a stroke. The mRS is a single item scale. It increases from 0 (no symptoms at all) to 6 (death).

At Day 90±7 days
Percentage of Participants With Barthel Index Score ≥95
Lasso di tempo: up to 90 days

The Barthel Index is an ordinal scale used to measure performance in activities of daily living (ADL). The Barthel Index consists of 10 items. The total score of the Barthel Index ranges from 0 to 100, and higher scores indicate better outcome.

up to 90 days
EQ-5D-5L score
Lasso di tempo: At Day 90±7 days

Health-related quality of life (the score on the EuroQol Group 5-Dimension 5-Level [EQ-5D-5L] questionnaire, range, -0.39 to 1, with higher scores indicating better quality of life)

At Day 90±7 days
Percentage of Participants With Symptomatic Intracerebral Haemorrhage (sICH)
Lasso di tempo: up to 36 hours

sICH via criteria adapted from the European Cooperative Acute Stroke Study (ECASS III), defined as any apparent extravascular blood in the brain or within the cranium that is associated with clinical deterioration defined by an NIHSS score increase of four points or more from baseline.

up to 36 hours
All-cause mortality
Lasso di tempo: up to 90 days

All-cause mortality at 90 days

up to 90 days
Percentage of Participants With Modified Rankin Scale (mRS) Score of 5 or 6
Lasso di tempo: At Day 90±7 days

Modified Rankin Scale (mRS) is a standardized measure that describes the extent of disability after a stroke. The mRS is a single item scale. It increases from 0 (no symptoms at all) to 6 (death).

At Day 90±7 days

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

19 dicembre 2025

Completamento primario (Effettivo)

1 novembre 2026

Completamento dello studio (Effettivo)

1 novembre 2026

Date di iscrizione allo studio

Primo inviato

21 novembre 2025

Primo inviato che soddisfa i criteri di controllo qualità

7 dicembre 2025

Primo Inserito (Effettivo)

19 dicembre 2025

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

3 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

1 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • 2025IITDA10

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Tipo di informazioni di supporto alla condivisione IPD

  • STUDIO_PROTOCOLLO
  • LINFA
  • RSI

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi